非ホジキンリンパ腫（NHL）の世界市場レポート 2025年

非ホジキンリンパ腫（NHL）市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR8.8％で154億2,000万米ドルに成長します。予測期間の成長は、高齢化人口の増加、標的療法の進歩、免疫療法の革新、精密医療アプローチ、認知度の向上、早期発見に起因すると考えられます。予測期間における主な動向としては、バイオシミラーの台頭、次世代シーケンサーの統合、car-t細胞療法の採用、新規化学療法剤、実臨床エビデンス、アウトカム調査などが挙げられます。

予想される非ホジキンリンパ腫市場の急増は、主にこの疾患の広範な有病率に後押しされています。リンパ系に発生するがんである非ホジキンリンパ腫は、人口の間でますます一般的になってきています。米国がん協会の2023年1月レポートが強調しているように、このがんは全がんの4％を占め、2023年には約80,550人の米国人が罹患し、推定20,180人が死亡すると予測されています。同様に、2022年5月にカナダがん協会が発表したデータによると、カナダでは同年11,400人が非ホジキンリンパ腫と診断され、3,000人が死亡しています。このような有病率の上昇は、非ホジキンリンパ腫市場の成長の原動力を強調しています。

急増する高齢者人口は、非ホジキンリンパ腫（NHL）市場拡大の重要な原動力となると思われます。高齢者におけるこの疾患の罹患率が高いことから、このセグメントに必要な専門的な治療とケアが市場の軌道を強調しています。2022年10月に世界保健機関（WHO）が予測したように、65歳以上と定義される世界の高齢者人口は2050年までに21億人に達し、2030年までに世界人口の6分の1を占めるようになります。その結果、高齢者人口の増加は非ホジキンリンパ腫（NHL）市場の拡大に大きく寄与します。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界非ホジキンリンパ腫（NHL） PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の非ホジキンリンパ腫（NHL）市場：成長率分析
• 世界の非ホジキンリンパ腫（NHL）市場の実績：規模と成長, 2019-2024
• 世界の非ホジキンリンパ腫（NHL）市場の予測：規模と成長, 2024-2029, 2034F
• 世界非ホジキンリンパ腫（NHL）総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の非ホジキンリンパ腫（NHL）市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• B細胞リンパ腫
• T細胞リンパ腫
• 世界の非ホジキンリンパ腫（NHL）市場治療別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 手術
• 幹細胞移植
• 化学療法
• 免疫療法
• 標的療法
• 放射線治療
• 世界の非ホジキンリンパ腫（NHL）市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 非経口
• その他の投与経路
• 世界の非ホジキンリンパ腫（NHL）市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• オンライン薬局
• その他の流通チャネル
• 世界の非ホジキンリンパ腫（NHL）市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• ホームケア
• 専門センター
• その他のエンドユーザー
• 世界の非ホジキンリンパ腫（NHL）市場、B細胞リンパ腫のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• びまん性大細胞型B細胞リンパ腫（DLBCL）
• 濾胞性リンパ腫
• 慢性リンパ性白血病（CLL）
• マントル細胞リンパ腫
• バーキットリンパ腫
• 辺縁帯リンパ腫
• 原発性縦隔B細胞リンパ腫
• 世界の非ホジキンリンパ腫（NHL）市場、T細胞リンパ腫のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 末梢性T細胞リンパ腫（PTCL）
• 未分化大細胞リンパ腫（ALCL）
• 皮膚T細胞リンパ腫（CTCL）
• T細胞リンパ芽球性リンパ腫
• 成人T細胞白血病/リンパ腫（ATLL）

第7章 地域別・国別分析

• 世界の非ホジキンリンパ腫（NHL）市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の非ホジキンリンパ腫（NHL）市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 非ホジキンリンパ腫（NHL）市場：競合情勢
• 非ホジキンリンパ腫（NHL）市場：企業プロファイル
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Eli Lilly and Co. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Novartis AG
• GlaxoSmithKline plc
• AbbVie Inc.
• AstraZeneca plc
• Takeda Pharmaceutical Company Limited
• Bristol Myers Squibb Co.
• Pfizer Inc.
• Celgene Corporation
• Sanofi S.A.
• Janssen Pharmaceuticals Inc.
• Johnson & Johnson
• Biogen Idec
• Boehringer Ingelheim GmbH
• Eisai Co. Ltd.
• Gilead Sciences

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 非ホジキンリンパ腫（NHL）市場2029：新たな機会を提供する国
• 非ホジキンリンパ腫（NHL）市場2029：新たな機会を提供するセグメント
• 非ホジキンリンパ腫（NHL）市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Non-Hodgkin lymphoma (NHL) is a cancer impacting the lymphatic system, characterized by abnormal white blood cell growth within the body's immune system, which typically fights infections.

The main types of NHL include B-cell lymphoma and T-cell lymphoma. B-cell lymphoma involves abnormal B lymphocytes in the immune system. Treatment for B-cell lymphomas often encompasses a combination of therapies such as chemotherapy, immunotherapy, targeted therapy, radiation therapy, and potentially stem cell transplants. Various treatment modalities including surgery, stem cell transplants, chemotherapy, immunotherapy, targeted therapy, and radiation therapy can be administered through different routes such as oral or parenteral methods. These treatments are available through diverse distribution channels including hospital pharmacies, retail outlets, online pharmacies, and others. They are utilized by various end-users including hospitals, homecare facilities, specialty centers, and other medical settings.

The non Hodgkin lymphoma market research report is one of a series of new reports from The Business Research Company that provides non Hodgkin lymphoma market statistics, including non Hodgkin lymphoma industry global market size, regional shares, competitors with a non Hodgkin lymphoma market share, detailed non Hodgkin lymphoma market segments, market trends and opportunities, and any further data you may need to thrive in the non Hodgkin lymphoma industry. This non Hodgkin lymphoma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The non hodgkin lymphoma (NHL) market size has grown strongly in recent years. It will grow from$10.11 billion in 2024 to $11.01 billion in 2025 at a compound annual growth rate (CAGR) of 8.9%. The growth in the historic period can be attributed to increased incidence of NHL, advancements in diagnostics, chemotherapy and immunotherapy, clinical research and drug development, improved survival rates

The non hodgkin lymphoma (NHL) market size is expected to see strong growth in the next few years. It will grow to $15.42 billion in 2029 at a compound annual growth rate (CAGR) of 8.8%. The growth in the forecast period can be attributed to growing aging population, advancements in targeted therapies, immunotherapy innovations, precision medicine approaches, increasing awareness and early detection. Major trends in the forecast period include rise of biosimilars, integration of next-generation sequencing, adoption of car-t cell therapies, novel chemotherapy agents, real-world evidence and outcomes research.

The anticipated surge in the non-Hodgkin lymphoma market is primarily fueled by the condition's widespread prevalence. Non-Hodgkin lymphoma, a cancer originating in the lymphatic system, is becoming increasingly common among populations. As highlighted by the American Cancer Society's January 2023 report, it constitutes 4% of all cancers and is projected to affect approximately 80,550 Americans in 2023, leading to an estimated 20,180 fatalities. Similarly, data from the Canadian Cancer Society in May 2022 indicated 11,400 diagnosed cases of non-Hodgkin lymphoma in Canada that year, resulting in 3,000 fatalities. This escalating prevalence underscores the driving force behind the non-Hodgkin lymphoma market's growth.

The burgeoning elderly population is poised to be a key driver for the expansion of the non-Hodgkin lymphoma (NHL) market. With a higher incidence of this ailment among older adults, the specialized care and treatment required for this segment emphasize the market's trajectory. As forecasted by the World Health Organization in October 2022, the global elderly population, defined as individuals aged 65 and above, is set to reach 2.1 billion by 2050, making up one-sixth of the world's populace by 2030. Consequently, the rising demographic of elderly individuals contributes significantly to the expansion of the non-Hodgkin lymphoma (NHL) market.

The non-Hodgkin lymphoma market is witnessing a significant trend in drug innovation, driving advancements in treatment options. Companies operating in this sector are actively pursuing product innovation to fortify their market positions. Genentech Inc.'s December 2022 FDA approval for Lunsumio, a novel bispecific antibody targeting relapsed or refractory follicular lymphoma, exemplifies this trend. This immunotherapy, a fixed-duration cancer treatment, provides readily available options for patients without delays in receiving treatment, based on positive outcomes from Phase II GO29781 research.

Major players in the non-Hodgkin lymphoma market are intensifying their focus on introducing cutting-edge immunotherapies such as Epcoritamab-bysp (EPKINLY) to gain a competitive edge. This investigational subcutaneous immunotherapy, targeting CD20-expressing B-cell malignancies, has exhibited promising results in clinical trials, notably in relapsed or refractory B-cell non-Hodgkin lymphoma. AbbVie Inc.'s November 2023 breakthrough therapy designation from the FDA for Epcoritamab-bysp (EPKINLY) in treating adult patients with relapsed or refractory follicular lymphoma marks a significant milestone. Additionally, the EMA's validation of a Type II application for epcoritamab (TEPKINLY) for the same indication is supported by encouraging results from the Phase 1/2 EPCORE NHL-1 clinical trial, involving 128 adult patients with relapsed or refractory CD20+ mature B-cell non-Hodgkin's lymphoma (NHL), including FL.

In August 2022, AstraZeneca plc, a prominent UK-based pharmaceutical and biotechnology entity, completed the undisclosed acquisition of TeneoTwo Inc. This strategic move aims to significantly enhance and diversify AstraZeneca's product lineup by incorporating oncology medications and a pipeline featuring TNB-486, a phase I clinical-stage CD19/CD3 T-cell engager specifically tailored for addressing relapsed and refractory B-cell non-Hodgkin lymphoma. TeneoTwo Inc., based in the US, specializes in biotechnological advancements within oncology, notably in the realm of treatments for NHL.

Major companies operating in the non hodgkin lymphoma (NHL) market include Bayer AG, Teva Pharmaceutical Industries Ltd., F. Hoffmann La Roche Ltd., Merck & Co. Inc., Eli Lilly and Co., Novartis AG, GlaxoSmithKline plc, AbbVie Inc., AstraZeneca plc, Takeda Pharmaceutical Company Limited, Bristol Myers Squibb Co., Pfizer Inc., Celgene Corporation, Sanofi S.A., Janssen Pharmaceuticals Inc., Johnson & Johnson, Biogen Idec, Boehringer Ingelheim GmbH, Eisai Co. Ltd., Gilead Sciences, Incyte Corporation, Karyopharm Therapeutics, Kite Pharma Inc., Kyowa Hakko Kirin Co. Ltd., MorphoSys AG, Nordic Nanovector ASA, Ono Pharmaceutical Co. Ltd., Seattle Genetics Inc., Spectrum Pharmaceuticals Inc.

North America was the largest region in the non-Hodgkin lymphoma (NHL) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the global non-Hodgkin lymphoma (NHL) market report during the forecast period. The regions covered in the non hodgkin lymphoma (nhl) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the non hodgkin lymphoma (nhl) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The non-Hodgkin lymphoma market includes revenues earned by entities by treating aggressive lymphomas, indolent lymphomas, Burkitt lymphoma, lymphoma and leukemia, and B-cell lymphomas. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Non Hodgkin Lymphoma (NHL) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on non hodgkin lymphoma (nhl) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for non hodgkin lymphoma (nhl) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The non hodgkin lymphoma (nhl) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: B-Cell Lymphoma; T-Cell Lymphoma
• 2) By Treatment: Surgery; Stem Cell Transplant; Chemotherapy; Immunotherapy; Targeted Therapy; Radiation Therapy
• 3) By Route of Administration: Oral; Parenteral; Other Routes of Administration
• 4) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy; Other Distribution Channels
• 5) By End-Users: Hospitals; Homecare; Specialty Centers; Other End Users
• Subsegments:
• 1) By B-Cell Lymphoma: Diffuse Large B-Cell Lymphoma (DLBCL); Follicular Lymphoma; Chronic Lymphocytic Leukemia (CLL); Mantle Cell Lymphoma; Burkitt Lymphoma; Marginal Zone Lymphoma; Primary Mediastinal B-Cell Lymphoma
• 2) By T-Cell Lymphoma: Peripheral T-Cell Lymphoma (PTCL); Anaplastic Large Cell Lymphoma (ALCL); Cutaneous T-Cell Lymphoma (CTCL); T-Cell Lymphoblastic Lymphoma; Adult T-Cell Leukemia/Lymphoma (ATLL)
• Companies Mentioned: Bayer AG; Teva Pharmaceutical Industries Ltd.; F. Hoffmann La Roche Ltd.; Merck & Co. Inc.; Eli Lilly and Co.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Non Hodgkin Lymphoma (NHL) Market Characteristics

3. Non Hodgkin Lymphoma (NHL) Market Trends And Strategies

4. Non Hodgkin Lymphoma (NHL) Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Non Hodgkin Lymphoma (NHL) Growth Analysis And Strategic Analysis Framework

• 5.1. Global Non Hodgkin Lymphoma (NHL) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Non Hodgkin Lymphoma (NHL) Market Growth Rate Analysis
• 5.4. Global Non Hodgkin Lymphoma (NHL) Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Non Hodgkin Lymphoma (NHL) Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Non Hodgkin Lymphoma (NHL) Total Addressable Market (TAM)

6. Non Hodgkin Lymphoma (NHL) Market Segmentation

• 6.1. Global Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• B-Cell Lymphoma
• T-Cell Lymphoma
• 6.2. Global Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Surgery
• Stem Cell Transplant
• Chemotherapy
• Immunotherapy
• Targeted Therapy
• Radiation Therapy
• 6.3. Global Non Hodgkin Lymphoma (NHL) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Parenteral
• Other Routes of Administration
• 6.4. Global Non Hodgkin Lymphoma (NHL) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Other Distribution Channels
• 6.5. Global Non Hodgkin Lymphoma (NHL) Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Homecare
• Specialty Centers
• Other End Users
• 6.6. Global Non Hodgkin Lymphoma (NHL) Market, Sub-Segmentation Of B-Cell Lymphoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Diffuse Large B-Cell Lymphoma (DLBCL)
• Follicular Lymphoma
• Chronic Lymphocytic Leukemia (CLL)
• Mantle Cell Lymphoma
• Burkitt Lymphoma
• Marginal Zone Lymphoma
• Primary Mediastinal B-Cell Lymphoma
• 6.7. Global Non Hodgkin Lymphoma (NHL) Market, Sub-Segmentation Of T-Cell Lymphoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Peripheral T-Cell Lymphoma (PTCL)
• Anaplastic Large Cell Lymphoma (ALCL)
• Cutaneous T-Cell Lymphoma (CTCL)
• T-Cell Lymphoblastic Lymphoma
• Adult T-Cell Leukemia/Lymphoma (ATLL)

7. Non Hodgkin Lymphoma (NHL) Market Regional And Country Analysis

• 7.1. Global Non Hodgkin Lymphoma (NHL) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Non Hodgkin Lymphoma (NHL) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Non Hodgkin Lymphoma (NHL) Market

• 8.1. Asia-Pacific Non Hodgkin Lymphoma (NHL) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Non Hodgkin Lymphoma (NHL) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Non Hodgkin Lymphoma (NHL) Market

• 9.1. China Non Hodgkin Lymphoma (NHL) Market Overview
• 9.2. China Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Non Hodgkin Lymphoma (NHL) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Non Hodgkin Lymphoma (NHL) Market

• 10.1. India Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Non Hodgkin Lymphoma (NHL) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Non Hodgkin Lymphoma (NHL) Market

• 11.1. Japan Non Hodgkin Lymphoma (NHL) Market Overview
• 11.2. Japan Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Non Hodgkin Lymphoma (NHL) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Non Hodgkin Lymphoma (NHL) Market

• 12.1. Australia Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Non Hodgkin Lymphoma (NHL) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Non Hodgkin Lymphoma (NHL) Market

• 13.1. Indonesia Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Non Hodgkin Lymphoma (NHL) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Non Hodgkin Lymphoma (NHL) Market

• 14.1. South Korea Non Hodgkin Lymphoma (NHL) Market Overview
• 14.2. South Korea Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Non Hodgkin Lymphoma (NHL) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Non Hodgkin Lymphoma (NHL) Market

• 15.1. Western Europe Non Hodgkin Lymphoma (NHL) Market Overview
• 15.2. Western Europe Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Non Hodgkin Lymphoma (NHL) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Non Hodgkin Lymphoma (NHL) Market

• 16.1. UK Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Non Hodgkin Lymphoma (NHL) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Non Hodgkin Lymphoma (NHL) Market

• 17.1. Germany Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Non Hodgkin Lymphoma (NHL) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Non Hodgkin Lymphoma (NHL) Market

• 18.1. France Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Non Hodgkin Lymphoma (NHL) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Non Hodgkin Lymphoma (NHL) Market

• 19.1. Italy Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Non Hodgkin Lymphoma (NHL) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Non Hodgkin Lymphoma (NHL) Market

• 20.1. Spain Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Non Hodgkin Lymphoma (NHL) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Non Hodgkin Lymphoma (NHL) Market

• 21.1. Eastern Europe Non Hodgkin Lymphoma (NHL) Market Overview
• 21.2. Eastern Europe Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Non Hodgkin Lymphoma (NHL) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Non Hodgkin Lymphoma (NHL) Market

• 22.1. Russia Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Non Hodgkin Lymphoma (NHL) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Non Hodgkin Lymphoma (NHL) Market

• 23.1. North America Non Hodgkin Lymphoma (NHL) Market Overview
• 23.2. North America Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Non Hodgkin Lymphoma (NHL) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Non Hodgkin Lymphoma (NHL) Market

• 24.1. USA Non Hodgkin Lymphoma (NHL) Market Overview
• 24.2. USA Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Non Hodgkin Lymphoma (NHL) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Non Hodgkin Lymphoma (NHL) Market

• 25.1. Canada Non Hodgkin Lymphoma (NHL) Market Overview
• 25.2. Canada Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Non Hodgkin Lymphoma (NHL) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Non Hodgkin Lymphoma (NHL) Market

• 26.1. South America Non Hodgkin Lymphoma (NHL) Market Overview
• 26.2. South America Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Non Hodgkin Lymphoma (NHL) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Non Hodgkin Lymphoma (NHL) Market

• 27.1. Brazil Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Non Hodgkin Lymphoma (NHL) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Non Hodgkin Lymphoma (NHL) Market

• 28.1. Middle East Non Hodgkin Lymphoma (NHL) Market Overview
• 28.2. Middle East Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Non Hodgkin Lymphoma (NHL) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Non Hodgkin Lymphoma (NHL) Market

• 29.1. Africa Non Hodgkin Lymphoma (NHL) Market Overview
• 29.2. Africa Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Non Hodgkin Lymphoma (NHL) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Non Hodgkin Lymphoma (NHL) Market Competitive Landscape And Company Profiles

• 30.1. Non Hodgkin Lymphoma (NHL) Market Competitive Landscape
• 30.2. Non Hodgkin Lymphoma (NHL) Market Company Profiles
  • 30.2.1. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. F. Hoffmann La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Eli Lilly and Co. Overview, Products and Services, Strategy and Financial Analysis

31. Non Hodgkin Lymphoma (NHL) Market Other Major And Innovative Companies

• 31.1. Novartis AG
• 31.2. GlaxoSmithKline plc
• 31.3. AbbVie Inc.
• 31.4. AstraZeneca plc
• 31.5. Takeda Pharmaceutical Company Limited
• 31.6. Bristol Myers Squibb Co.
• 31.7. Pfizer Inc.
• 31.8. Celgene Corporation
• 31.9. Sanofi S.A.
• 31.10. Janssen Pharmaceuticals Inc.
• 31.11. Johnson & Johnson
• 31.12. Biogen Idec
• 31.13. Boehringer Ingelheim GmbH
• 31.14. Eisai Co. Ltd.
• 31.15. Gilead Sciences

32. Global Non Hodgkin Lymphoma (NHL) Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Non Hodgkin Lymphoma (NHL) Market

34. Recent Developments In The Non Hodgkin Lymphoma (NHL) Market

35. Non Hodgkin Lymphoma (NHL) Market High Potential Countries, Segments and Strategies

• 35.1 Non Hodgkin Lymphoma (NHL) Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Non Hodgkin Lymphoma (NHL) Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Non Hodgkin Lymphoma (NHL) Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer